| Composition : | 2.5mg/2.5ml,4mg/4ml | | Indications : | Metastatic carcinoma of the ovary after failure of initial or subsequent chemo therapy. Small cell lung cancer disease after failure of first line chemotherapy. | | Adverse Effects : | Bone marraw suppression (Primarily neutropenia, thrombocytopenic anaemia, abdominal discomfort. | | Dosage : | Before administration of topotecan. Patient should have a baseline neutrophil count of >1500 cells/mm3 and a platelet count of >10000 cell/mm3.
The recommended starting dose is 1.5mg/m2 by IV infusion over 30 minutes daily for 5 consecutive days, starting pm day 1 or 21 day course. In absence of tumor progression a minimum of four courses are recommended, as tumour response may be delayed. | | Purity : | Not less than 99%. | |
 | |  |
© Health Biotech Limited. All Rights Reserved (Terms of Use)